I would trust the company to take the best decision based on the data and strategic timing and moves.
Yup, I am in the same place. It is what it is. My whole point is that sometimes (unplanned-new knowledge-good news) can be developed during trials. We expect AVXL thinkers to be on the leading edge of changes, in a positive way. Trial endpoint are whatever they are, a best effort estimate based on history. No one has ever done what AVXL has/is doing, we know that also. There is no history except decades of continuous failure.
When that is the FDA (PD/PDD/AD...)trial legacy at some point strong challenges to the overall learning process are warranted. At some point a history of continuous failures must be evaluated by rational 3rd parties and informed body's.
AVXL is not going to miss, that is my bet. BTW, IMO they most likely already know that.